CAJ | 학술논문

索拉菲尼是治疗晚期原发性肝细胞癌的分子靶向药物,但肝癌对其耐药性的出现,影响了该药物的治疗效果.目前有明确证据提示肝癌对索拉菲尼耐药的发生与上皮间质转化、肝癌干细胞及肝癌的异质性有重要关系,PI3K/AKt信号通路作为重要的“共同信号通路”参与了上述过程.在索拉菲尼治疗同时,补充性的抑制PI3K/AKt信号通路是目前加强索拉菲尼治疗肝癌效果的方法.
색랍비니시치료만기원발성간세포암적분자파향약물,단간암대기내약성적출현,영향료해약물적치료효과.목전유명학증거제시간암대색랍비니내약적발생여상피간질전화、간암간세포급간암적이질성유중요관계,PI3K/AKt신호통로작위중요적“공동신호통로”삼여료상술과정.재색랍비니치료동시,보충성적억제PI3K/AKt신호통로시목전가강색랍비니치료간암효과적방법.
Sorafenib is a molecular targeted drug for the treatment of advanced primary liver cancer.However,along with the occurrence of drug resistance,the therapeutic effect was effected.At present,there is clear evidence that the emergence of drug resistance of live cancer is closely related to the epithelial-mesenchymal transition,liver cancer stem cells and the heterogeneity of liver cancer,and the PI3K/AKt signaling pathway as the vital "common signaling channel" was involved in the above mentioned process.From this we can conclude that complementary inhibtion of PI3K/AKt signaling pathway at the same time is the method that can strengthen the effect of sorafenib on the treatment of liver cancer so far.